Gomar et al
Same molecule, different FDA indications, different coverage logic
[PubMed] [Google Scholar] 80.Boutaud O, Aronoff DM, Richardson JH, Marnett LJ, Oates JA
56 Our findings build on two previously reported PDAC-specific characteristics, namely, 1st RAS signaling driving glutamine metabolism for ROS homeostasis 22,50,51 and 2nd mitochondrial dependency upon genetic loss of the KRAS oncogene, 41 and connect them with a more generally described cancer cell state associated with therapy resistance, characterized by a dependence on lipid peroxidation defense pathways
Empagliflozin did not increase the incidence of tumors in female rats dosed at 100, 300, or 700 mg/kg/day (up to 72 times the exposure from the maximum clinical dose of 25 mg)
Durham Peptides supplies the Wolverine Stack 10mg (C$79.99) 5mg BPC-157 + 5mg TB-500, Janoshik-verified per component